High expression of NLRP12 predicts poor prognosis in patients with intracranial glioma

Background:Intracranial gliomas are the most common primary central nervous system tumors in humans, and glioblastoma multiforme is the most malignant intracranial glioma. The nucleotide-binding domain leucine-rich repeat (NLR)-containing family are crucial regulators of inflammatory and innate immune responses. NLRP12 codes for the monarch-1 protein, which regulates immune responses in humans. Data from a next-generation sequencing database indicated that NLRP12 expression is increased in glioma cells. However, the relationship between NLRP12 levels and gliomas is unclear. Methods:To explore the role of NLRP12-related translation factors and proteins in glioma, we evaluated the clinical data and paraffin sections from glioma patients. The expression of NLRP12 was evaluated using immunohistochemical analysis, and clinical parameters were analyzed using chi-square and Kaplan-Meier survival tests. Results:The degree of malignancy and prognosis highly correlated with NLRP12 levels. In addition, the siRNA-mediated downregulation of NLRP12 in glioma cell lines decreased proliferation, invasion, and migration. The levels of VEGF, N-cadherin, and cyclin D1 were downregulated after knockdown of NRLP12 in glioma cell lines, as observed using western blotting in vitro. Knockdown of NLRP12 attenuated the tumor progression in vivo. Conclusion:The expression of NLRP12 may be an independent prognostic factor and a potential target for the treatment of intracranial glioma.

Automated summary

The expression level of NLRP12 is closely associated with the malignancy and prognosis of gliomas. Knockdown of NLRP12 can reduce the proliferation, invasion, and migration of glioma cells, as well as downregulate the expression levels of VEGF, N-cadherin, and cyclin D1. Therefore, NLRP12 may serve as an independent prognostic factor and a potential target for the treatment of intracranial gliomas.